BR112022016887A2 - Composições tópicas de diclofenaco e métodos - Google Patents

Composições tópicas de diclofenaco e métodos

Info

Publication number
BR112022016887A2
BR112022016887A2 BR112022016887A BR112022016887A BR112022016887A2 BR 112022016887 A2 BR112022016887 A2 BR 112022016887A2 BR 112022016887 A BR112022016887 A BR 112022016887A BR 112022016887 A BR112022016887 A BR 112022016887A BR 112022016887 A2 BR112022016887 A2 BR 112022016887A2
Authority
BR
Brazil
Prior art keywords
diclofenac
methods
topical compositions
compositions
topical
Prior art date
Application number
BR112022016887A
Other languages
English (en)
Portuguese (pt)
Inventor
N R Carrara Dario
Grenier Amaud
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of BR112022016887A2 publication Critical patent/BR112022016887A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BR112022016887A 2020-02-27 2021-02-25 Composições tópicas de diclofenaco e métodos BR112022016887A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062982589P 2020-02-27 2020-02-27
PCT/NL2021/050125 WO2021172987A1 (en) 2020-02-27 2021-02-25 Topical diclofenac compositions and methods

Publications (1)

Publication Number Publication Date
BR112022016887A2 true BR112022016887A2 (pt) 2022-10-18

Family

ID=74858737

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016887A BR112022016887A2 (pt) 2020-02-27 2021-02-25 Composições tópicas de diclofenaco e métodos

Country Status (9)

Country Link
US (1) US20230157979A1 (cg-RX-API-DMAC7.html)
EP (1) EP4110320A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023515539A (cg-RX-API-DMAC7.html)
CN (1) CN115279360A (cg-RX-API-DMAC7.html)
AU (1) AU2021228521B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022016887A2 (cg-RX-API-DMAC7.html)
CA (1) CA3169241A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022010593A (cg-RX-API-DMAC7.html)
WO (1) WO2021172987A1 (cg-RX-API-DMAC7.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2538856C (en) 2003-10-10 2010-06-29 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
EP2055298A1 (en) * 2007-10-30 2009-05-06 Novartis AG Topical composition
US20120157536A1 (en) * 2010-12-20 2012-06-21 Polytherapeutics, Inc. Composition for transdermal administration of non-steroidal anti-flammatory drug
US9713590B2 (en) * 2011-07-28 2017-07-25 Cadila Healthcare Limited Method for treatment of pain and inflammation
BR112015000329A2 (pt) 2012-07-12 2017-06-27 Ferring Bv formulações de diclofenac
US20140113970A1 (en) * 2012-10-22 2014-04-24 Mallinckrodt LLC Covidien Dispensing system
US9468618B2 (en) * 2014-12-12 2016-10-18 Lupin Atlantis Holdings Sa Topical pharmaceutical gel composition of diclofenac sodium

Also Published As

Publication number Publication date
EP4110320A1 (en) 2023-01-04
JP2026116929A (ja) 2026-07-14
CA3169241A1 (en) 2021-09-02
US20230157979A1 (en) 2023-05-25
JP2023515539A (ja) 2023-04-13
AU2021228521A1 (en) 2022-10-13
MX2022010593A (es) 2022-12-13
CN115279360A (zh) 2022-11-01
AU2021228521B2 (en) 2026-06-04
WO2021172987A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
CL2022003077A1 (es) Proteínas que se unen a nkg2d, cd16 y clec12a
UY40021A (es) Inhibidores lisina acetiltransferasa 6a (kat6a) y usos de los mismos
BR112023018472A2 (pt) Composições de psilocibina, métodos de produção e métodos de uso das mesmas
BR112018013245A2 (pt) método e aparelho para administração óxido nítrico com drogas suplementares
AR060306A1 (es) Terapia de combinacion de anticuerpos contra ctla4
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
BR112017016087A2 (pt) formulações para coxim articular adiposo e métodos de uso das mesmas
BR112023006024A2 (pt) Terapias de imuno-oncologia com conjugados de il-2
BR112021024886A2 (pt) Métodos de tratar a doença de fabry em pacientes com insuficiência renal
MX2021005992A (es) Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
BR112023024209A2 (pt) Composições que compreendem um agente terapêutico de redirecionamento de células t e um agente terapêutico anti-cd44
WO2021191689A3 (en) Treatment of inflammatory diseases with peptides and pharmaceutical compositions
MX2019004402A (es) Metodos para el tratamiento de las condiciones relacionadas con la inflamacion utilizando moduladores antiinflamatorios y metabolicos pluripotentes.
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
CL2023002446A1 (es) Inhibidores de enzimas
BR112021017957A2 (pt) Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo
CO2023007955A2 (es) Ésteres de ácidos dicarboxílicos para el tratamiento de enfermedades y padecimientos asociados con la toxina fosfolipasa d
MX2022014577A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
CO2023000194A2 (es) Administración de sulcardina para el tratamiento de fibrilación auricular aguda
BR112022000155A2 (pt) Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma
WO2022026092A3 (en) Method of treatment of neutrophil-driven inflammatory pathologies
BR112022003687A2 (pt) Método para tratar tinnitus, composição farmacêutica para administração intranasal, e, dose unitária pulverizável de ocitocina
CL2024000891A1 (es) Composiciones líquidas orales de enzalutamida
AU2023409158A1 (en) Methods of delivering therapeutic agents, and lipid compositions

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]